Prosonix has announced the appointment of Geoff Down to the newly-created position of Chief Medical Officer, effective immediately. Down, who has extensive experience in clinical development and has served various roles, some as a consultant pharmaceutical physician, for Pfizer, Respivert, GSK, and other companies, will oversee clinical development of the Pronsonix pipeline, which includes a fluticasone MDI, a glycopyrrolate MDI, and a series of inhaled combination therapies.
Prosonix CEO David Hipkiss commented, “Geoff’s appointment is pivotal for Prosonix as we aim to become a fully-fledged pharmaceutical company operating within the respiratory space. Geoff’s extensive clinical, regulatory and medical experience makes him ideally suited to lead Prosonix’ clinical development. We are on course to file our lead candidate PSX1001 for asthma later this year and expect to announce further progress on the clinical strategy for PSX1002 and the PSX2000 combination series in the near future. With the recent appointment of Rob Crocker as Head of Regulatory Affairs, I believe that we are in a strong position to successfully implement and advance our clinical and commercial strategy.”
Down responded, “There is still a large need for better and more effective treatments despite the development of new respiratory therapeutics. I have been very impressed with Prosonix’ drug development strategy, based on its proprietary particle engineering technology, which has shown the potential to create more effective and safer respiratory medicines for patients. I am excited to be joining the Company as it enters the next stage of growth and look forward to contributing my expertise to help it achieve its upcoming clinical and regulatory milestones.”
As Prosonix transitions from a particle engineering company to a pharmaceutical company, it has been adding personnel to oversee its development program and recently appointed Rob Crocker as Head of Regulatory Affairs.
Read the Prosonix press release.
